{
  "content": "Full Text\nFull Text (PDF)\nScopus (134)\nPubMed\nGoogle Scholar\nFor this reason, addition of a rate control drug may not be needed when using amiodarone, dronedarone, sotalol for rhythm control. The choice of rate control drugs depends on symptom burden, presence of comorbidities (e.g., heart failure) and potential side-effects and interactions.\nNon-pharmacological rate control can also be achieved with the “pace-and-ablate” strategy, consisting of implantation of a permanent pacemaker followed by atrioventricular node ablation.\nBeta-blockers\nBeta-blockers antagonise sympathetic beta1-receptor activity in the atrioventricular node and thus slow the ventricular rate.2\n2.\nVan Gelder, I.C. ∙ Rienstra, M. ∙ Crijns, H.J.G.M. ∙ et al.\nRate control in atrial fibrillation\nLancet. 2016; 388:818-828",
  "source": "https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00220-X/fulltext",
  "chunk_id": "87f556f4-dbc6-4be7-8944-46b333c8fe9e",
  "similarity_score": 0.3107379674911499,
  "query": "beta-blockers rate control atrial fibrillation metoprolol propranolol heart rate ventricular response",
  "rank": 45,
  "title": "Atrial fibrillation: better symptom control with rate and rhythm management",
  "authors": "Dhiraj Gupta, Michiel Rienstra, Isabelle C. van Gelder, Laurent Fauchier",
  "year": "2024",
  "journal": "The Lancet Regional Health – Europe",
  "reference": "Gupta, D., Rienstra, M., van Gelder, I. C., & Fauchier, L. (2024). Atrial fibrillation: better symptom control with rate and rhythm management. The Lancet Regional Health – Europe, 37100801. https://doi.org/10.1016/j.lanepe.2023.100801",
  "doi": "10.1016/j.lanepe.2023.100801",
  "chunk_index": 88,
  "total_chunks": 154,
  "retrieved_at": "2025-07-24T22:33:19.810119"
}